Method of treating depression
View Patent ↗Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject.
1. A method for treating major depression or dysthymia in a subject, the method comprising
selecting a subject diagnosed with a disorder consisting of major depression or dysthymia using specific clinical criteria for major depression or dysthymia; and
administering to the subject 30 to 50 unit equivalents of a Botulinum toxin to one or both of a corrugator supercilii muscle and a procerus muscle, to cause paralysis of one or both of the corrugator supercilii muscle and the procerus muscle; and
wherein the subject is also treated with a therapeutically effective amount of a selective serotonin reuptake inhibitor (SSRI);
thereby decreasing the ability of the subject to frown and treating the disorder consisting of major depression or dysthymia in the subject.
2. The method of claim 1 , wherein the Botulinum toxin is Botulinum toxin A.
3. The method of claim 2 , wherein about 20-40 Unit equivalents of Botulinum toxin type A is administered to the one or both of the corrugator supercilii muscle and the procerus muscle.
4. The method of claim 3 , further comprising administering an additional dose of about 30-50 Unit equivalents of Botulinum toxin type A to one or both of the corrugator supercilii muscle or the procerus muscle after about two to six months.
5. A method for treating primary intermittent anxiety and major depression in a subject, the method comprising
selecting a subject that has a disorder consisting of primary intermittent anxiety and major depression using specific clinical characteristics for primary intermittent anxiety and major depression and
administering to the subject 30-50 Unit equivalents of Botulinum toxin to one or both of a corrugator supercilii and a procerus muscle to cause paralysis of the corrugator supercilii or muscle, the procerus muscle, or both; and
wherein the subject is also treated with a therapeutically effective amount of a selective serotonin reuptake inhibitor (SSRI);
thereby decreasing the ability of the subject to scowl or appear sad, and thereby treating the disorder consisting of primary anxiety and major depression in the subject.
6. The method of claim 5 , wherein the Botulinum toxin is Botulinum toxin A.
7. The method of claim 6 , wherein about 20-40 Unit equivalents of Botulinum toxin type A is administered to one or both of the corrugator supercilii and the procerus muscle.
8. The method of claim 7 , further comprising administering an additional dose of about 30-50 Unit equivalents of Botulinum toxin type A to one or both of the corrugator supercilii muscle and the procerus muscle after about two to six months.
9. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of an additional modality of treatment for depression.
10. The method of claim 9 , wherein the additional modality of treatment comprises administration of an antidepressant, psychotherapy, electroconvulsive therapy, light therapy, or electromagnetic radiation.
11. The method of claim 5 , further comprising administering to the subject a therapeutically effective amount of an additional modality of treatment for depression.
12. The method of claim 11 , wherein the modality of treatment comprises administration of an antidepressant, psychotherapy, electroconvulsive therapy, light therapy, or electromagnetic radiation.
13. The method of claim 1 , wherein the subject has a disorder consisting of major depression.
14. The method of claim 1 , wherein the subject has a disorder consisting of dysthymia.
15. The method of claim 1 , wherein the subject has frown lines, glabellar lines or both.
16. The method of claim 5 , wherein the subject has frown lines, glabellar lines or both.